neuroendocrine tumors/triglyceride

Веза се чува у привремену меморију

Изаберите тип сортирања

7 резултати

Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The determinants for gastroenteropancreatic neuroendocrine tumors (GEP-NET) recent burden are matters of debate. Obesity and metabolic syndrome (MetS) are well established risks for several cancers even though no link with GEP-NETs was yet established. Our aim in this study was to investigate

Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET).

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE Hypertriglyceridaemia (HTG) is a potentially serious side effect of everolimus therapy. We here report a case of severe HTG in an everolimus-treated patient and provide recommendations for its management. METHODS The patient was a 70-year-old woman, being treated with everolimus for a

Risk factors associated with rectal neuroendocrine tumors: a cross-sectional study.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND The incidence of rectal neuroendocrine tumors (NET) has been increasing since the implementation of the screening colonoscopy. However, very little is known about risk factors associated with rectal NETs. We examined the prevalence of and the risk factors for rectal NETs in a Korean

Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The mTOR inhibitor everolimus is effective against advanced pancreatic neuroendocrine tumors (pNETs). However, it can cause metabolic adverse events, such as hyperglycemia, hypertriglyceridemia and hypercholesterolemia. In this work we aimed at evaluating the impact of systemic and tumor lipid

Tratamiento hipolipemiante de la pancreatitis aguda secundaria a hipertrigliceridemia severa por everolimus en un paciente con tumor neuroendocrino.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Everolimus is an mTOR inhibitor, approved as a treatment for cancer and as an immunosuppressant agent in solid organ transplantation; it frequently produces toxic metabolic effects, particularly of the most severe kind. Its use can cause hyperglycemia, hypercholesterolemia and hypertriglyceridemia;

Everolimus causing severe hypertriglyceridemia and acute pancreatitis.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Everolimus is an mTOR inhibitor commonly used to treat metastatic pancreatic neuroendocrine tumors (pNETs) and renal cell carcinoma, and for posttransplant immunosuppression. This report presents a case of a 36-year-old man being treated with everolimus for a metastatic pNET who developed severe

Investigation of human pancreatic cancer tissues by Fourier Transform InfraRed HyperSpectral Imaging (FTIR-HSI).

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

FTIR-HSI (Fourier-Transform InfraRed HyperSpectral Imaging) provides hyperspectral images containing both morphological and chemical information. It is widely applied in the biomedical field to detect tumor lesions, even at the early stage, by identifying specific spectral biomarkers. Pancreatic

Придружите се нашој
facebook страници

Herbal & Natural Medicine

Најкомплетнија база лековитог биља подржана науком

Ради на 55 језика
Биљни лекови потпомогнути науком
Препознавање биљака по слици
Интерактивна ГПС мапа - означите биље на локацији (ускоро)
Читајте научне публикације повезане са вашом претрагом
Претражите лековито биље по њиховим ефектима
Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима